Core Insights - Tarsus Pharmaceuticals has launched a direct-to-consumer TV campaign for XDEMVY, the first FDA-approved treatment for Demodex blepharitis, which affects approximately 25 million people in the U.S. [1][4][7] Group 1: Campaign Overview - The campaign titled "Your Mitey Problem" creatively illustrates the impact of Demodex mites on patients' eyelids, showcasing a 'party' of mites causing irritation and inflammation [3][4] - The campaign aims to educate patients about Demodex blepharitis and encourage them to consult eye care providers regarding XDEMVY [4][5] - The multi-channel campaign is currently live on connected TV devices, streaming channels, and includes digital and social media components [5] Group 2: Product Information - XDEMVY (lotilaner ophthalmic solution) 0.25% is designed to target and eradicate Demodex mites, addressing the root cause of Demodex blepharitis [8] - The active ingredient, lotilaner, selectively inhibits GABA-Cl channels, effectively eradicating the mites [8] - Clinical trials involving over 800 patients demonstrated that XDEMVY met primary and secondary endpoints with no serious treatment-related adverse events [8][10] Group 3: Company Background - Tarsus Pharmaceuticals focuses on unmet medical needs, particularly in eye care, and is advancing a pipeline that includes treatments for various diseases [9] - The company is also investigating additional products for conditions such as Meibomian Gland Disease and Rosacea, all currently in Phase 2 trials [9]

Group 1 - The company has a strong academic foundation with expertise in finance and medicine, enhancing its capabilities in the financial sector [1] - The firm specializes in income investing and biotech/pharma investing, leveraging nearly a decade of experience [2][3] - The organization focuses on identifying both short-term catalyst-driven opportunities and long-term investment strategies in the biotech sector [3] Group 2 - Subscribers receive regular portfolio trade alerts and have access to an interactive chat feature, promoting engagement and support [4] - The company has published a best-selling book on biotech investing and offers educational courses, further establishing its authority in the field [4] - The firm provides custom biotech analysis upon request, catering to specific investor needs [5]

IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in ...

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.20%. A quarter ago, it was expected that this company would post a loss of $1.15 per share when it actually produced a loss of $1.01, delivering a surprise of 12.17%. Over the last four quarters, the compa ...

About Tarsus Pharmaceuticals, Inc. Media Contact: Adrienne Kemp Sr. Director, Corporate Communications (949) 922-0801 akemp@tarsusrx.com IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second q ...

Investor Contact: David Nakasone Head of Investor Relations (949) 620-3223 DNakasone@tarsusrx.com IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences: William Blair Growth Stock Conference Jeff Farrow, Chief Financial and Chief Strategy Offic ...

IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences: Contacts: Media Contact: Adrienne Kemp Sr. Director, Corporate Communications (949) 922-0801 akemp@tarsusrx.com Investor Contact: David Nakasone Head of Investor Relations (949) 620-3223 DN ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants David Nakasone - Head of Investor Relations Bobby Azamian - Chief Executive Officer and Chairman Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - Chief Financial Officer and Chief Strategy Officer Sesha Neervannan - Chief Operating Officer Conference Call Participants Eddie Hickman - Guggenheim Securities Balaji - Barclays Francois Brisebois - Oppenheimer Jason Gerberry - Bank of Am ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ____ . Commission File Number: 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-47178 ...

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements Generated $24.7 million in net product sales of XDEMVY , an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients ® Secured multiple commercial payer contracts and remain on-track for broad commercial coverage by the end of 2024 and Medicare coverage beginning in 2025 Expanded sales force on-track to be in the field by the end of the third quarter 2024 Strengthened financial position wi ...